Background-Approximately half of patients with heart failure die suddenly as a result of ventricular arrhythmias.
C ongestive heart failure (HF) is a leading cause of mortality and morbidity worldwide. Approximately 50% of HF patients die of sudden cardiac death (SCD) attributed to ventricular arrhythmias (Ͼ300 000 in the United States annually). 1, 2 A large fraction of these arrhythmias are thought to be initiated by focal triggered mechanisms, such as spontaneous diastolic Ca 2ϩ release from cardiac myocyte ryanodine receptors (RyR2) on the sarcoplasmic reticulum (SR), which activates an arrhythmogenic depolarizing inward Na ϩ /Ca 2ϩ exchange (NCX) current. 3, 4 Indeed, in HF there is enhanced diastolic SR Ca 2ϩ release and other changes in electrophysiological substrate that greatly enhance the propensity for triggered arrhythmias. Likewise, patients with inherited RyR2 point mutations exhibit catecholaminergic polymorphic ventricular tachycardia, a known cause of SCD with sensitivity to adrenergic conditions such as exercise or stress. 5, 6 HF is a chronic hyperadrenergic state, and a prominent theory suggested that ␤-adrenergic activation of protein kinase A (PKA) destabilized RyR2 through the loss of binding by FKBP12. 6, 7, 8 contributing to SR Ca 2ϩ leak and consequent systolic dysfunction and arrhythmogenesis. However, subsequent work showed that inhibition of Ca 2ϩ /cal-modulin-dependent protein kinase II (CaMKII) rather than PKA was sufficient to reverse the arrhythmogenic SR Ca 2ϩ leak in HF 9 and that CaMKII mediates the ␤-adrenergic-induced increase in SR Ca 2ϩ leak even in normal myocytes. 10 Thus, in HF, CaMKII phosphorylation of RyR2 may be more important for arrhythmogenic events leading to SCD.
Clinical Perspective on p 2679
CaMKII, which is upregulated and more active in HF, 4 can phosphorylate and modulate numerous Ca 2ϩ transport and ion channel proteins in cardiac myocytes, including RyR2 and voltage-gated Ca 2ϩ , Na ϩ , and K ϩ channels, all of which could contribute to arrhythmogenesis. 11 Moreover, transgenic overexpression of CaMKIV or CaMKII␦ (the predominant myocyte isoform) induces HF and cardiac arrhythmias, [12] [13] [14] [15] whereas inhibition and CaMKII␦ knockout limit the progression of HF and arrhythmias. 16, 17 One weakness of currently available genetic models in which CaMKII activity is inhibited by gene deletion or transgenic expression of inhibitory peptides is that they do not permit selective evaluation of specific downstream phosphorylation targets affected by CaMKII upregulation or inhibition. Given the role of CaMKII phosphorylation of RyR2 in both HF and diastolic SR Ca 2ϩ release, we sought to define the role of CaMKII phosphorylation of RyR2 specifically in cardiac arrhythmogenesis. Therefore, we generated and studied knockin mouse models in which the CaMKII phosphorylation site on RyR2 was either genetically inhibited or constitutively activated. Here we tested whether (1) the phosphomimetic S2814D mutant RyR2 alone increased the susceptibility to ventricular arrhythmias and (2) whether the nonphosphorylatable S2814A mutant prevented arrhythmias associated with cardiac hypertrophy and failure.
Methods

Animals
Generation of RyR2-S2814A knockin and AC3I transgenic mice was described previously. 5, 17 RyR2-S2814D knockin mice were created by an approach similar to that described for RyR2-S2814A knockin mice 5 
Coimmunoprecipitation Assay
RyR2 was immunoprecipitated from heart lysates with the use of an anti-RyR2 antibody (Thermo Scientific, Rockland, Ill) incubated with protein A-Sepharose beads (Rockland, Gilbertsville, Pa) at room temperature for 1 hour. For coimmunoprecipitation, antibodyattached beads were incubated with heart lysate aliquots containing 1000 g total protein at 4°C overnight. After incubation, beads were washed with detergent-free coimmunoprecipitation buffer and resuspended in 2ϫ lithium dodecyl sulfate buffer (Invitrogen, Carlsbad, Calif) containing ␤-mercaptoethanol. Samples were heated at 50°C for 15 minutes and were resolved on 4% to 20% Criterion sodium dodecyl sulfate polyacrylamide electrophoresis gels (Bio-Rad) for detection of RyR2 and FKBP12.6.
RyR2 Phosphorylation Assay
RyR2 was immunoprecipitated, and beads were washed with phosphorylation-assay buffer containing 50 mmol/L Tris-Cl (pH 7.5), 10 mmol/L MgCl 2 , 2 mmol/L dithiothreitol, 0.1 mmol/L Na 2 EDTA, 5 mmol/L NaF, 1 mmol/L Na 3 VO 4 , 1ϫ protease inhibitors, and 1ϫ phosphatase inhibitors and resuspended in phosphorylation-assay buffer supplemented with 100 mol/L cold ATP and 1.5 Ci [␥- 32 P] ATP (Perkin Elmer, Waltham, Mass). The phosphorylation reaction was initiated by adding CaMKII (250 U per reaction), which was preactivated according to the manufacturer's (New England Biolabs, Ipswich, Mass) instructions in the absence or presence of the CaMKII inhibitor KN-93 (10 mol/L) (Calbiochem, San Diego, Calif). Reaction mixtures were incubated at 30°C for 20 minutes and stopped by adding 2ϫ lithium dodecyl sulfate buffer (Invitrogen) containing ␤-mercaptoethanol. Samples were heated at 50°C for 10 minutes and resolved on 5% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels. The protein gels were dried and exposed to Kodak BioMax maximum resolution films.
Western Blot Analyses
Heart lysates were prepared from flash-frozen mouse hearts as described previously. 18 Lysates were taken from mice at rest ( 
Histology
A transverse section of the heart was fixed in 10% buffered formalin for 48 hours. After paraffin embedding and sectioning, 5-m sections were stained with hematoxylin-eosin for cell morphology and Masson's trichrome for interstitial fibrosis as described. 18 
Confocal Imaging
Ca 2ϩ sparks were recorded in saponin-permeabilized (50 g/mL) or intact ventricular cardiomyocytes with the use of a Zeiss LSM510 confocal microscope. For experimental details, refer to the onlineonly Data Supplement.
Single-Channel Recordings
Single-channel recordings of wild-type (WT) or S2814D RyR2 were performed and analyzed under voltage-clamp conditions as described previously 19 (see also the online-only Data Supplement).
Transthoracic Echocardiography
Mice were anesthetized with 1.5% isoflurane in 95% O 2 . Body temperature was maintained at 36°C to 37°C on a heated platform, and ECGs and temperature were continuously monitored. Cardiac function was assessed with the use of a VisualSonics VeVo 770 Imaging System (VisualSonics, Toronto, Ontario, Canada) equipped with a high-frequency 30-MHz probe, as described. 20, 21 Data analysis was performed with the use of VisualSonics software (VisualSonics).
ECG Telemetry
Twenty-three animals (11 S2814D and 12 WT) were studied with ECG telemetry according to published methods 22 (see the onlineonly Data Supplement).
Transverse Aortic Constriction
TAC was performed as described previously in detail (see also the online-only Data Supplement). 21, 24, 25 
Statistical Analysis
Continuous variables were expressed as meanϮSEM; whenever the distribution was skewed, medians with the first and third quartiles were expressed. Continuous variables were evaluated with an unpaired Student t test or ANOVA. The Mann-Whitney test was used to compare continuous variables with a skewed distribution. Categorical data were expressed as percentages and were compared with the Fisher exact test. The Kaplan-Meier survival curve was evaluated by the log-rank test. PϽ0.05 was considered statistically significant.
Results
We generated a knockin mouse model in which aspartic acid replaces serine at RyR2-2814 (S2814D) to mimic constitutive phosphorylation of RyR2 by CaMKII ( Figure I in the online-only Data Supplement). CaMKII can phosphorylate RyR2 immunoprecipitated from WT hearts but not from S2814D mice ( Figure 1A) . Furthermore, CaMKII inhibition by KN-93 prevents RyR2 phosphorylation by CaMKII in WT hearts but has no effect in S2814D hearts, indicating that S2814 is the major CaMKII target site of RyR2 ( Figure 1A ). FKBP12.6 binding to RyR2 can alter RyR2 function, but we found that the S2814D mutation did not alter FKBP12.6 binding to RyR2 in cardiac homogenates ( Figure 1B) , as found in an earlier report. 19 At baseline, cardiac structure and function are similar in young (3-month-old) WT and S2814D mice as determined by echocardiography (Table and Table I in the online-only Data Supplement). Transverse hematoxylin-eosin-stained sections from WT and S2814D hearts showed that there were no significant differences in right ventricular wall thickness (WT, 0.58Ϯ0.17 mm; S2814D, 0.47Ϯ0.14 mm; Pϭ0. 10 Figure  1C and 1D ). Quantitative analysis of Masson's trichrome stainings revealed no differences in the amount of interstitial fibrosis when WT (0.06Ϯ0.02% of total surface area) and S2814D mouse hearts (0.07Ϯ0.02%; Pϭ0.61) ( Figure 1E and 1F) were compared. Wheat germ agglutinin staining and quantification of myocardial cell size revealed no differences in myocyte surface areas in WT (2311Ϯ166 m 2 ) and S2814D (2315Ϯ256 m 2 ) mouse hearts (Pϭ0.99) ( Figure   Figure 1 . Figure 1I) .
At the myocyte level, HF and CaMKII overexpression (and activation) enhance SR Ca 2ϩ leak (manifested as increased Ca 2ϩ sparks or waves mediated by RyR2) and can thus serve as the molecular trigger for arrhythmia. 26 To determine how SR Ca 2ϩ leak is altered in young S2814D and S2814A mice, we used confocal microscopy to image local SR Ca 2ϩ release events, or Ca 2ϩ sparks, in permeabilized isolated cardiomyocytes ( Figure 2A ). At baseline, Ca 2ϩ spark frequency was significantly increased in S2814D (9.8Ϯ0.5/s per 100 m) versus WT mice (6.4Ϯ0.3/s per 100 m; PϽ0.001; Figure  2A and 2B). Activation of endogenous CaMKII significantly increased Ca 2ϩ spark frequency in WT myocytes (9.9Ϯ0.5/s per 100 m) but had no additional effect in S2814D cells (which were already at this higher level: 10.2Ϯ0.6/s per 100 m). In S2814A myocytes, Ca 2ϩ spark frequency was comparable to WT at baseline both before (5.1Ϯ0.1/s/ 100 m) and after activation of CaMKII (6.1Ϯ0.2/s per 100 m). The small rise with CaMKII was entirely attributable to enhanced SR Ca 2ϩ content ( Figure 2C and 2D) and did not significantly alter Ca 2ϩ spark amplitude, full duration at half-maximum, full width at half-maximum, or maximum Ca 2ϩ release ( Figure II in the online-only Data Supplement). Inclusion of the specific CaMKII inhibitory peptide AIP (1 mol/L) prevented CaMKII-dependent activation of Ca 2ϩ spark frequency in WT cells but did not alter Ca 2ϩ spark frequency in S2814D myocytes ( Figure 2B ). Combined, these results show that constitutive RyR2-S2814 pseudophosphorylation mimics maximal CaMKII activation of WT RyR2 in ventricular myocytes and that S2814 is the only functionally important CaMKII site with respect to these measurements.
We was similar in WT, S2814D, and S2814A cardiomyocytes (Pϭ0.43; Figure 3A and 3B). However, the time constant of twitch [Ca 2ϩ ] i decline was significantly lower in S2814D (403.8Ϯ18 ms; PϽ0.05) compared with WT (274.8Ϯ13 ms) and S2814A (238Ϯ18 ms). Moreover, SR Ca 2ϩ load (assessed by rapid application of 10 mmol/L caffeine) was 50% lower in S2814D compared with WT or S2814A myocytes (Pϭ0.02; Figure 3A and 3C). This is presumably due to the slightly reduced SERCA2a function and higher diastolic SR Ca 2ϩ leak in S2814D myocytes (see above) and also evidenced by significantly higher Ca 2ϩ spark frequency in intact S2814D myocytes versus WT or S2814A myocytes ( Figure  IIIA and IIIB in the online-only Data Supplement). However, other parameters such as Ca 2ϩ spark amplitude, full duration at half-maximum, full width at half-maximum, and rate of rise were unchanged among the groups ( Figure IIIC through IIIF in the online-only Data Supplement Figure) . Note that CaMKII␦ C transgenic mouse myocytes and rabbit HF myocytes also exhibit enhanced leak and reduced SR Ca 2ϩ load. 9, 12 There was no statistical difference in NCX function, measured as the time constant of [Ca 2ϩ ] i decline during a caffeine-induced Ca 2ϩ transient, among the 3 mouse groups: WT (ϭ1.9Ϯ0.2 seconds), S2814D (ϭ2.2Ϯ0.6 seconds), and S2814A (ϭ1.7Ϯ0.2 seconds) (Pϭ0.54). However, the S2814D mice exhibited enhanced fractional SR Ca 2ϩ release (ratio of twitch/caffeine-induced Ca 2ϩ transient) compared with WT or S2814A mice (PϽ0.001; Figure 3D ). Thus, S2814D mice maintain normal Ca 2ϩ transients (and cardiac function) with a smaller SR Ca 2ϩ load but a larger fractional release at each contraction. This is consistent with prior work suggesting that CaMKII-dependent RyR2 phosphorylation sensitizes RyR2 to a given Ca 2ϩ current trigger at a given SR Ca 2ϩ load. 27 Thus, RyR2 phosphorylation at S2814 activates both diastolic and systolic RyR2 Ca 2ϩ release. To directly assess RyR2 single-channel opening, we extracted microsomes containing RyR2 from young WT and S2814D mouse hearts and reconstituted them in lipid bilayers. RyR2-S2814D channels exhibited much higher open probability (54.3% [interquartile range, 25.8% to 86.5%]) compared with RyR2 from WT mice (1.0% [interquartile range, 0.9% to 2.5%]; PϽ0.001; Figure 3E and 3F). It is likely, however, that the relative increase in open probability of S2814D mutant channels will be more modest in vivo because the frequency of Ca 2ϩ sparks in S2814D myocytes was only increased 2-fold. The single-channel and whole-cell experiments demonstrate that pseudophosphorylation of RyR2 at the S2814 CaMKII site increases the open probability of RyR2, resulting in diastolic Ca 2ϩ leak. We then used young (3-to 4-month-old) S2814D knockin mice to evaluate the effects of CaMKII-mediated RyR2 phosphorylation on arrhythmogenesis in structurally normal hearts. ECG telemeters were implanted in both WT and S2814D mice to allow recording of ambulatory ECG waveforms. S2814D mice had normal heart rhythm at rest, with unaltered electrophysiological parameters such as heart rate, depolarization intervals (PQ, QRS), and repolarization intervals (QTc) (Table II in the online-only Data Supplement). Moreover, the ventricular effective refractory period was also unaffected in S2814D mice (Table III in 
van Oort et al CaMKII Phosphorylation of RyR2 Causes Arrhythmias
Pϭ0.002), which is indicative of ventricular ectopic arrhythmic activity ( Figure 4A and 4B). Given that hearts of S2814D mice were structurally and electrically normal at rest but exhibited ventricular ectopy upon ␤-adrenergic stimulation, we considered that the model phenotype might resemble catecholaminergic polymorphic ventricular tachycardia. To further test S2814D mice for predisposition to ventricular arrhythmias under more stringent catecholaminergic conditions, 5, 28 we injected caffeine and epinephrine (120 mg/kg and 2 mg/kg IP, respectively). There was a significantly increased incidence of sustained ventricular tachycardia in S2814D mice (71%) compared with WT mice (13%; Pϭ0.04) ( Figure 4C and 4D) . This is consistent with the presence of a proarrhythmogenic substrate caused by CaMKII pseudophosphorylation of RyR2. One S2814D mouse exhibited persistent ventricular tachycardia after caffeine and epinephrine that deteriorated into bradycardia and then asystole ( Figure 4E ). Thus, CaMKII-mediated RyR2 phosphorylation promotes in vivo ventricular arrhythmias and increases the risk of SCD.
To further differentiate the role of CaMKII activation of RyR2 from the effects of PKA activation, we sought to examine the role of elevated heart rate on arrhythmogenesis by performing in vivo intracardiac electrophysiology studies. Programmed electric stimulation with the use of ventricular burst pacing was performed to compare cardiac susceptibility with ventricular ectopic activity in WT and S2814D mice. Burst pacing evoked sustained ventricular tachycardia in 53% of S2814D mice compared with 6% of WT mice (Pϭ0.006; Figure 5A and 5B). Consistent with previous studies, 19 rapid pacing induced CaMKII but not PKA phosphorylation of RyR2, whereas the S2814D mutation inhibited CaMKII phosphorylation of RyR2 underpaced and unpaced conditions ( Figure 5 and Figure IVA and IVB in the online-only Data Supplement). In contrast, pacing increased phospholamban phosphorylation at the CaMKII site T17 ( Figure 5E and 5F) but not the PKA site S16 ( Figure IVC and IVD in the online-only Data Supplement) in both S2814D and WT mice, suggesting that enhanced SR Ca 2ϩ loading due to SERCA2a stimulation facilitates induction of ventricular tachycardia in S2814D mice.
Finally, treatment with the ␤-adrenergic receptor blocker propranolol (3 mg/kg) did not significantly alter the incidence of ventricular arrhythmia induction (S2814D, 50%; WT, 0%) ( Figure 5B ). Because sudden changes in heart rate may induce a reflex sympathetic response and change in blood pressure, we also performed control experiments in which the arterial blood pressure was continuously monitored while the right ventricle was paced from 500 to 800 bpm at 100-bpm intervals. The blood pressure at a pacing rate of 800 bpm was not significantly higher (3.1Ϯ0.1%; Pϭ0.88) than at 500 bpm, thus excluding the possibility that a reflex sympathetic response due to blood pressure changes is evoked in mice receiving electrophysiology studies.
To test whether CaMKII targets other than RyR2 may contribute to the observed arrhythmogenesis, we crossed S2814D mice with AC3I transgenic mice, in which the CaMKII-inhibitory peptide AC3I reduces CaMKII activity in the heart. 17 S2814D:AC3I double-mutant mice experienced a slight decline in arrhythmia incidence (33% versus 53% in S2814D), suggesting that the effects of CaMKII on other targets, such as L-type Ca 2ϩ current 29 or phospholamban, might promote SR Ca 2ϩ loading and arrhythmogenesis. However, when these experiments were repeated after injec- mice before and after isoproterenol challenge. C, Representative telemetric ECG tracings from WT and S2814D mice after injection of caffeine and epinephrine (Caf/Epi; 120 mg/kg and 2 mg/kg IP, respectively). D, Ventricular tachycardia (VT) was observed in the majority of S2814D mice after caffeine and epinephrine. E, ECG waveform showing baseline ECG tracing of a S2814D mouse in sinus rhythm (heart rate, 431 bpm). On the injection of caffeine and epinephrine, heart rate increased to 480 bpm, and PVCs occurred starting at 5 minutes after injection of caffeine and epinephrine. At 10 minutes, episodes of nonsustained ventricular tachycardia (NSVT) started occurring (570 bpm), eventually deteriorating into an episode of sustained ventricular tachycardia starting at 20 minutes (ventricular rate varying between 588 and 667 bpm). Immediately after this ventricular tachycardia episode, the mouse developed progressive heart block followed by asystole and death at 25 minutes. N is indicated in bar graphs. The Mann-Whitney U test was used to compare absolute PVC incidence; Fisher exact test was used to evaluate ventricular tachycardia incidence. *PϽ0.05 vs WT.
tion of the ␤-adrenergic receptor agonist isoproterenol (0.5 mg/kg IP), the incidence of sustained ventricular tachycardia was not reduced in S2814D-AC3I mice (66%) ( Figure 5B ). These results suggest that PKA activation and phosphorylation of Ca 2ϩ handling proteins (eg, phospholamban, L-type Ca 2ϩ channel, and RyR2), even in the absence of CaMKII activation, can also enhance SR Ca 2ϩ loading and promote arrhythmias in S2814D mice.
Previously, other groups have demonstrated that transgenic overexpression of CaMKII-␦ c induces HF in mice, [12] [13] [14] [15] and therefore we sought to define the specific role of CaMKII phosphorylation of RyR2 in progression to HF. As mentioned above, S2814D mice had no significant echocardiographic differences compared with WT littermates at 3 months of age (Table) . However, at 12 months of age, S2814D mice demonstrated a significant increase in LV posterior wall diameter and end-diastolic diameter and a small but significant decrease in ejection fraction (52.4Ϯ1.8%) compared with WT mice (56.9Ϯ0.7%; Pϭ 0.005) (Figure 6A through 6C and Table; PϽ0.05).
Additionally, we performed TAC in young (3-to 4-monthold) S2814D and WT mice to evaluate the effects of constitutive CaMKII phosphorylation of RyR2 on the development of HF and arrhythmias. At 4 weeks after TAC, CaMKII phosphorylation of RyR2 was not significantly elevated in WT mice ( Figure VA and VB in the online-only Data Supplement). Moreover, phosphorylation of S2808 on RyR2 was not altered in WT and S2814D mice after TAC ( Figure  VC and VD in the online-only Data Supplement). However, survival was significantly lower for S2814D mice (40%) compared with WT mice (91%; Pϭ0.02) 3 weeks after TAC surgery ( Figure 6D ). To determine whether the difference in survival was caused by arrhythmias, we repeated TAC studies in 5 WT and 5 S2814D mice in which a telemetric ECG transmitter was implanted 1 week before TAC. These studies revealed that the 2 S2814D mice in this group that died after TAC experienced episodes of ventricular arrhythmias immediately preceding death, whereas none of the WT mice died within 3 weeks after TAC ( Figure 6E ). These results implicate CaMKII phosphorylation of RyR2 as an important factor contributing to arrhythmogenesis and sudden death in HF.
Next, we assessed whether prevention of CaMKIImediated phosphorylation of RyR2 at S2814 could ameliorate ventricular arrhythmogenesis in mice with HF. To test this hypothesis, we used knockin mice in which S2814 of RyR2 is replaced by alanine (S2814A) to genetically inhibit CaMKII phosphorylation of RyR2. 5 Surgical TAC was performed in young (3-to 4-month-old) WT and S2814A mice to induce Figure 5 . CaMKII phosphorylation of RyR2 is critical for development of ventricular arrhythmias in normal and failing hearts. A, Representative ECG tracings after injection of 0.5 mg/kg isoproterenol and intracardiac overdrive pacing. WT mice exhibited normal sinus rhythm after intracardiac pacing, whereas S2814D mice were predisposed to development of ventricular tachycardia (VT). B, Percent incidence of overdrive pacing-induced ventricular tachycardia in WT, S2814D, and S2814D:AC3I mice with (ϩ) and without (Ϫ) ␤-adrenergic agonist isoproterenol (Iso) (0.5 mg/kg IP) and propranolol ␤-blocker (BB) (3 mg/kg IP). C, Representative Western blot of the RyR2 CaMKII site (S2814) in WT and S2814D mice before and after intracardiac pacing. D, WT mice have a significant increase in phosphorylation at the CaMKII site S2814, whereas S2814D mice cannot be phosphorylated at this site. E, Representative Western blot of the phospholamban (PLN) CaMKII site (T17) before and after intracardiac pacing. F, There is a significant increase in phosphorylation of phospholamban by CaMKII in WT mice. N is indicated in bar graphs. Fisher exact test was used to compare ventricular tachycardia incidence data; an unpaired Student t test was used to compare phosphorylation data. *PϽ0.05, **PϽ0.01 vs WT treatment-matched control; #PϽ0.05 vs S2814D nonpaced control.
HF. After echocardiography at 8 weeks after TAC, WT and S2814A mice were matched such that, on average, both groups exhibited equal levels of cardiac dysfunction (Table  IV in the online-only Data Supplement). Similar to patients with HF, 30 WT mice subjected to TAC developed an increased propensity toward ventricular arrhythmias. Programmed electric stimulation revealed that 75% (6 of 8) of WT mice developed nonsustained ventricular tachycardia after overdrive pacing at 8 weeks after TAC ( Figure 7A and 7B). In contrast, only 14% (1 of 7) of S2814A mice developed nonsustained ventricular tachycardia (Pϭ0.04).
Western blots with the use of a phosphoepitope-specific Figure 6 . CaMKII phosphorylation of RyR2 causes cardiac dilation, loss of contractility, and early death from arrhythmias. Echocardiographic measurements of LV posterior wall diameter (LVPWD) (A), end-diastolic diameter (EDD) (B), and ejection fraction (EF) (C) in S2814D and WT mice from 3 to 12 months are shown. S2814D mice have significantly increased diastolic dimensions and reduction in ejection fraction vs WT mice (nϭ14, both groups). D, Kaplan-Meier survival curve in S2814D (nϭ10) and WT (nϭ11) mice 3 weeks after TAC. E, Representative ECG tracing of an arrhythmogenic death in a S2814D mouse that died after TAC surgery. Sudden death after ventricular tachycardia (VT) was observed only in S2814D mice and in none of the WT mice after TAC. *PϽ0.05 vs WT. Student t test was used to compare echocardiographic data. A log-rank test was used to evaluate survival analysis. antibody revealed increased CaMKII phosphorylation of RyR2 in WT mice after TAC, whereas the S2814 phosphorylation site could not be phosphorylated in S2814A mice, as expected ( Figure 7C and 7D) . In contrast, phosphorylation of the PKA site S2808 was not altered in WT and S2814A mice compared with sham-operated controls ( Figure 7E and 7F). These results suggest that CaMKII phosphorylation of S2814 on RyR2 is an essential signaling event that promotes ventricular arrhythmias in TAC-induced HF. Taken together, our data in S2814D and S2814A mice demonstrate that CaMKII phosphorylation of RyR2 at this site is critical for the development of cardiac arrhythmia.
Discussion
Previous work has demonstrated that increased CaMKII activity in failing hearts may contribute to abnormal Ca 2ϩ handling, contractile failure, and arrhythmogenesis. 9, 15 The novel knockin mice, which express only the CaMKII phosphomimetic S2814D-mutant RyR2 or only nonphosphorylatable S2814A at this RyR2 site, have allowed unique tests of the importance of CaMKII phosphorylation of RyR2 at the cardiomyocyte and whole-animal level. First, both biochemical and functional data ( Figure 1A and 1B) indicate that RyR2 phosphorylation at S2814 is the principal and possibly only site mediating CaMKII phosphorylation of RyR2 in mouse myocytes under physiological conditions. There may be other CaMKII target sites on RyR2, 31 but they are obvious neither in our CaMKII-dependent 32 P incorporation into S2814D mutant RyR2 nor at the functional level, as evidenced by Ca 2ϩ release events. Additionally, CaMKII activation in WT myocytes did not produce a stronger increase in the Ca 2ϩ spark frequency than the S2814D myocytes exhibit at baseline. In addition, in the S2814A myocytes, the very small CaMKII-induced increase in Ca 2ϩ spark frequency was explained by an enhanced SR Ca 2ϩ load (presumably secondary to SR Ca 2ϩ -ATPase stimulation via CaMKIIdependent phospholamban phosphorylation). Note that a primary enhancement of RyR2 activity would decrease rather than increase SR Ca 2ϩ load. A second major conclusion is that constitutive activation of the RyR2 CaMKII site increases the risk for ventricular arrhythmias in vivo, even in the absence of structural heart disease in young mice. Quantitative analysis of cardiac dimensions, fibrosis, and cardiac myocyte size revealed that structural remodeling is unlikely to be a significant cause of arrhythmogenesis in young S2814D mice. The elevated arrhythmia risk is also independent of altered binding of FKBP12.6 and can occur in the absence of increased PKA activity on elevated heart rate. Interestingly, even though S2814D mice exhibit an increased incidence of Ca 2ϩ sparks, ectopic activity was not observed under resting conditions. At baseline, the myocytes may be effectively compensated by the combination of reduced SR Ca 2ϩ load and increased fractional SR Ca 2ϩ release during excitation-contraction coupling, such that the diastolic SR Ca 2ϩ leak is insufficient to produce triggered arrhythmias unless SR Ca 2ϩ load is driven toward WT levels (for example, after phosphorylation of phospholamban).
Our findings have potentially important clinical implications with respect to arrhythmias in HF because CaMKII expression, activity, and phosphorylation of RyR2 at S2814, with resultant diastolic SR Ca 2ϩ leak, are all enhanced in patients and animals with HF. 9, 16 The level of S2814 phosphorylation is increased by Ϸ50% to 100% in failing hearts compared with nonfailing control hearts. 9, 16, 32, 33 Most of our studies were performed in homozygous S2814D mice to determine the physiological consequences of RyR2 phosphorylation. Whereas it is unlikely that S2814 on RyR2 will be maximally phosphorylated for prolonged amounts of time in patients or animals with HF, this model enabled us to elucidate the specific effects of RyR2 phosphorylation by CaMKII. Preliminary studies in heterozygous S2814D mice revealed arrhythmia incidences similar to those of homozygous S2814D mice (2 of 3 developed pacing-induced arrhythmia after isoproterenol administration), suggesting that our data may also be relevant as a model of RyR2 hyperphosphorylation seen in failing hearts.
Indeed, our findings suggest that CaMKII-dependent RyR2 phosphorylation may be a critical mediator of the high incidence of arrhythmias in human HF. Moreover, our data suggest that among the several CaMKII targets that have the potential to be proarrhythmic (Na ϩ , Ca 2ϩ , and K ϩ channels), the RyR2 effects may predominate. The activating effect of CaMKII on RyR2 resembles the gain-of-function phenotype seen in inherited RyR2 mutations that are associated with catecholaminergic polymorphic ventricular tachycardia. On the other hand, our data show that ventricular arrhythmias can be triggered in S2814D mice in the absence of increased PKA activation and PKA phosphorylation of RyR2 and phospholamban. Conversely, ␤-adrenergic stimulation increased the likelihood of arrhythmogenesis, possibly because of enhanced Ca 2ϩ entry with increased SR Ca 2ϩ loading via SERCA2a/phospholamban. On the basis of prior studies, 34 enhanced SR Ca 2ϩ release via RyR2 is likely sufficient to trigger Ca 2ϩ waves and depolarizing transient inward current via NCX, although this remains to be confirmed in S2814D mice in future studies.
A third conclusion is that when RyR2 S2814 cannot be phosphorylated (S2814A), arrhythmias associated with the development of HF are prevented. This extends the aforementioned conclusion in an important way: In addition to being proarrhythmogenic in normal and failing hearts, CaMKII-dependent phosphorylation of RyR2-S2814 may be an essential component for the triggered arrhythmias in HF, at least in the context of pressure overload-induced HF, as examined here. This may extend to recent observations that CaMKII␦ knockout mice exhibit reduced transition to HF (and reduced RyR2-S2814 phosphorylation) during similar pressure overload-induced HF. 16 The dramatic increase in diastolic SR Ca 2ϩ leak (and Ca 2ϩ spark frequency) in CaMKII␦ transgenic mice reduces SR Ca 2ϩ load severely enough to depress systolic dysfunction, despite enhanced fractional SR Ca 2ϩ release. 12 Thus, CaMKII-dependent phosphorylation of RyR2-S2814 may be critical in both arrhythmogenesis and systolic dysfunction in HF.
Prior reports suggested that PKA-dependent hyperphosphorylation of RyR2 at S2808 and consequent FKBP12.6
van Oort et al CaMKII Phosphorylation of RyR2 Causes Arrhythmiasdissociation are causative in the enhanced SR Ca 2ϩ leak and arrhythmias in HF, 35, 36 although key aspects of these observations remain highly controversial. 37 Our results here do not resolve this controversy, although, in our TAC model, RyR2 phosphorylation at the CaMKII site and not the PKA site was increased. Moreover, it is clear that CaMKII-dependent phosphorylation of RyR2 (or pseudophosphorylation) at S2814, which occurs in HF, can strongly activate RyR2 in myocytes and increase the propensity for arrhythmias and may even accelerate the transition from hypertrophy to HF. 21 It has been shown that inhibition of calmodulin binding to RyR2 by selective mutations in the binding site leads to a severe phenotype characterized by early-onset cardiomyopathy and postnatal death between days 9 and 16. 38 Because calmodulin is thought to inhibit RyR2, disrupting the calmodulin binding site on RyR2 may lead to increased Ca 2ϩ release. However, the functional effects of disrupting calmodulin binding appear to be more severe compared with increasing Ca 2ϩ release by constitutive CaMKII phosphorylation (RyR2-ADA mice are lethal before weaning; RyR2-S2814D mice appear to have a normal lifespan). Thus, SR Ca 2ϩ leak through RyR2-S2814D mice was sufficient to promote ventricular arrhythmias but not severe enough to cause earlyonset cardiomyopathy due to activation of Ca 2ϩ -dependent hypertrophic signaling pathways.
In conclusion, our data suggest that increased CaMKII phosphorylation of RyR2 Ca 2ϩ release channels at S2814 promotes the development of ventricular arrhythmias in mice even in the absence of structural heart disease. Our findings may have clinical implications with respect to arrhythmias in patients with congestive HF because the activity of CaMKII is chronically enhanced in failing hearts. We have also demonstrated that inhibition of CaMKII phosphorylation of RyR2 can prevent ventricular arrhythmias in mice with HF. Thus, the effects of CaMKII on RyR2 may be a critical factor in the generation of arrhythmias in patients with HF, although this remains to be studied in humans. Our findings may lead to the development of more specific therapies that could modify the level of CaMKII phosphorylation of RyR2, thus reducing diastolic Ca 2ϩ leak and ultimately death from arrhythmias. Such novel antiarrhythmic agents, once tested in randomized trials, may ultimately provide new avenues for treating ventricular arrhythmias and preventing sudden cardiac death in patients with HF.
